A new device, worn like a wristwatch to help control tremor in people with Parkinson’s disease, is now available in the U.S. from its developer, Cala Health. Called the Cala kIQ System, the wearable device is the first to be cleared by the U.S. Food and Drug Administration…
Accidental falls and co-existing conditions, or comorbidities, like fatigue, depression, and sleeping problems are frequent in older adults with either Parkinson’s disease or essential tremor syndrome, suggesting “similar central origins” for these two disorders, a study reported. Its data also support essential tremor being found in older Parkinson’s patients, and Parkinson’s in those…
Cala Health has raised $77 million that will support further innovations of the company’s expertise — bioelectronic medicine — to explore conditions beyond essential tremor, including Parkinson’s disease and other neurological conditions. The funding also will help expand patient access to the company’s devices, which includes Cala Trio, a…
The U.S. Food and Drug Administration (FDA) has named Cala Trio a breakthrough device as a potential wrist-worn treatment of action tremors in the hands of adults with Parkinson’s disease. This designation is given to medical devices with the potential to more effectively treat diseases that are life-threatening or irreversibly debilitating. It…
Using Cala Health’s non-invasive therapeutic device Cala Trio for 40 minutes twice daily effectively helped to reduce hand tremors within three months, results from a clinical study show. The results, “Study Design, Baseline Demographics, and Interim Results from the Prospective Study for Symptomatic Relief of Essential…
Get regular updates to your inbox.
